Collaborators
Sign in to add collaborator| Jonathan D. Dinman | collaborator | 1995-2001 | Rutgers - Robert Wood Johnson Medical School |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Luban J, Sattler R, Mühlberger E, et al. (2020) The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines. Virus Research. 198246 |
| Luban J, Sattler R, Mühlberger E, et al. (2020) The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines. Biorxiv : the Preprint Server For Biology |
| Friesen WJ, Johnson B, Sierra J, et al. (2018) The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential. Plos One. 13: e0206158 |
| Cao L, Weetall M, Trotta C, et al. (2018) Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties. Molecular Cancer Therapeutics |
| Friesen WJ, Trotta CR, Tomizawa Y, et al. (2017) The nucleoside analog clitocine is a potent and efficacious readthrough agent. Rna (New York, N.Y.) |
| Weetall M, Davis T, Elfring G, et al. (2016) Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein Translation. Clinical Pharmacology in Drug Development. 5: 296-305 |
| Weetall M, Davis T, Elfring G, et al. (2016) Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein Translation Clinical Pharmacology in Drug Development |
| Naryshkin NA, Weetall M, Dakka A, et al. (2014) Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science (New York, N.Y.). 345: 688-93 |
| Bushby K, Finkel R, Wong B, et al. (2014) Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle & Nerve. 50: 477-87 |
| Kerem E, Konstan MW, De Boeck K, et al. (2014) Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine. 2: 539-47 |